

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on May 18, 2025

Monoclonal Mouse Anti-Human Cytokeratin, Clone AE1/AE3

RRID:AB_2132885

Type: Antibody

Proper Citation

(Agilent Cat# M3515, RRID:AB_2132885)

Antibody Information

URL: http://antibodyregistry.org/AB_2132885

Proper Citation: (Agilent Cat# M3515, RRID:AB_2132885)

Target Antigen: Cytokeratin

Host Organism: mouse

Clonality: monoclonal

Comments: Info: Used By NYUIHC-1191.

Info: Original Manufacturer: Dako. Now part of Agilent.

Info: Used by Czech Centre for Phenogenomics

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Monoclonal Mouse Anti-Human Cytokeratin, Clone AE1/AE3

Description: This monoclonal targets Cytokeratin

Clone ID: AE1/AE3

Antibody ID: AB_2132885

Vendor: Agilent

Catalog Number: M3515

Alternative Catalog Numbers: M351529-2

Record Creation Time: 20231110T082358+0000

Record Last Update: 20241115T131207+0000

Ratings and Alerts

- Used by Czech Centre for Phenogenomics - Czech Centre for Phenogenomics
<https://www.phenogenomics.cz/>

No alerts have been found for Monoclonal Mouse Anti-Human Cytokeratin, Clone AE1/AE3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 41 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Wu SG, et al. (2025) Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis. Clinical and translational medicine, 15(1), e70149.

Bjørnstad OV, et al. (2024) Global and single-cell proteomics view of the co-evolution between neural progenitors and breast cancer cells in a co-culture model. EBioMedicine, 108, 105325.

Shrestha H, et al. (2024) The Janus kinase 1 is critical for pancreatic cancer initiation and progression. Cell reports, 43(5), 114202.

Lior C, et al. (2024) Mapping the tumor stress network reveals dynamic shifts in the stromal oxidative stress response. Cell reports, 43(5), 114236.

Xu H, et al. (2024) CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. iScience, 27(7), 109978.

Gao Y, et al. (2024) Cross-tissue human fibroblast atlas reveals myofibroblast subtypes with distinct roles in immune modulation. Cancer cell, 42(10), 1764.

Remy D, et al. (2024) TFEB triggers a matrix degradation and invasion program in triple-

negative breast cancer cells upon mTORC1 repression. *Developmental cell*.

Chowdhury S, et al. (2023) Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer. *Cell*, 186(16), 3476.

Kim K, et al. (2023) Spatial and clonality-resolved 3D cancer genome alterations reveal enhancer-hijacking as a potential prognostic marker for colorectal cancer. *Cell reports*, 42(7), 112778.

Olukoya AO, et al. (2023) Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer. *Journal of the Endocrine Society*, 7(10), bvad117.

Kameyama H, et al. (2023) Needle biopsy accelerates pro-metastatic changes and systemic dissemination in breast cancer: Implications for mortality by surgery delay. *Cell reports. Medicine*, 4(12), 101330.

Biswas S, et al. (2023) Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers. *Immunity*, 56(11), 2570.

Hawley JE, et al. (2023) Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer. *Cancer cell*, 41(11), 1972.

Liu Y, et al. (2023) A SOX9-B7x axis safeguards dedifferentiated tumor cells from immune surveillance to drive breast cancer progression. *Developmental cell*, 58(23), 2700.

Maistriaux L, et al. (2023) Reconstruction of the human nipple-areolar complex: a tissue engineering approach. *Frontiers in bioengineering and biotechnology*, 11, 1295075.

Li Z, et al. (2022) Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer. *NPJ breast cancer*, 8(1), 62.

Langille E, et al. (2022) Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer. *Cancer discovery*, 12(12), 2930.

Anadon CM, et al. (2022) Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. *Cancer cell*, 40(5), 545.

Knudsen ES, et al. (2022) CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities. *Cell reports*, 38(9), 110448.

Leader AM, et al. (2021) Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. *Cancer cell*, 39(12), 1594.